Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.

about

Nanotherapeutics for multiple myeloma.

P2860

Q52559684-A76FD9E6-454A-4D12-AABE-4638B9FB42AC

P2860

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.

Item

http://www.wikidata.org/entity/Q41545464

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pomalidomide in the treatment ...... elopment and place in therapy.

@en

type

Item

label

Pomalidomide in the treatment ...... elopment and place in therapy.

@en

prefLabel

Pomalidomide in the treatment ...... elopment and place in therapy.

@en

P1476

Pomalidomide in the treatment ...... elopment and place in therapy.

@en

P2093

Agustín Martín-García

http://www.w3.org/2001/XMLSchema#string

Alberto Jiménez Morales

http://www.w3.org/2001/XMLSchema#string

Ana María Del Valle Díaz de la Guardia

http://www.w3.org/2001/XMLSchema#string

Carlos Gustavo García Collado

http://www.w3.org/2001/XMLSchema#string

Carolina Alarcón-Payer

http://www.w3.org/2001/XMLSchema#string

Dolores Sánchez-Rodríguez

http://www.w3.org/2001/XMLSchema#string

José Cabeza Barrera

http://www.w3.org/2001/XMLSchema#string

Manuel Jurado Chacón

http://www.w3.org/2001/XMLSchema#string

Rafael Ríos-Tamayo

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Identification of a primary target of thalidomide teratogenicity

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Interpretation of cytogenetic results in multiple myeloma for clinical practice

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

New investigational drugs with single-agent activity in multiple myeloma

Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells

Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

P304

2399-2408

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/DDDT.S115456

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28860711

http://www.w3.org/2001/XMLSchema#string

P921

carboxylic acid

multiple myeloma

P932

5574598

http://www.w3.org/2001/XMLSchema#string

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.

about

P2860

P2860

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P407

P478

P5008

P577

P698

P921

P932